| Abstract | Cilj istraživanja: Ciljevi ovog istraživanja bili su odrediti parametre regulacije glikemije (mjereno vrijednostima glukoze natašte i HbA1c) te ispitati postoji li razlika s obzirom na terapiju, dob, spol i ITM ispitanika. Nacrt studije: Presječno istraživanje s povijesnim podatcima Ispitanici: U istraživanje je uključeno 102 ispitanika oba spola s dijagnozom šećerne bolesti tipa 2 koji su pregledani u ambulantama Doma zdravlja Osijek Materijali i metode: U ambulantama obiteljske medicine prikupljeni su sljedeći podatci: dob, spol, tjelesna masa i tjelsna visina te podatci iz laboratorijskih nalaza (glukoza natašte, HbA1c, AST, ALT, ureja, kreatinin, ukupni kolesterol, HDL kolesterol, LDL kolesterol, trigliceridi) Rezultati: Vrijednosti HbA1c i medijan koncentracije glukoze najniži su kod ispitanika na terapiji oralnim antidijabeticima (6,9 % i 7,9 mmol/L) dok su kod ispitanika na kombiniranoj terapiji vrijednosti najveće (9 % i 9,8 mmol/L). Povezanost vrijednosti HbA1c i glukoze s dobi, indeksom tjelesne mase i spolom nije potvrđena. Zaključak: Statistički značajna razlika uočena je između vrijednosti HbA1c i vrste terapije ispitanika, odnosno razlika je uočena između ispitanika na oralnim antidijabeticima i onih na kombiniranoj terapiji. Nije uočena statistički značajna razlika u parametrima regulacije glikemije (glukoza natašte, HbA1c) s obzirom na dob, spol i indeks tjelesne mase ispitanika. |
| Abstract (english) | Aim of the study: The aim of this study was to asses glycemic control (fasting plasma glucose and glycated Hemoglobin A1c) of both genders, with type 2 diabetes mellitus at Osijek Health Center and to examine whether there is a difference in the concentration of these components in relation to therapy, age, gender and body mass index. Study design: Cross-sectional study with historical data Participants: The study included 102 participants, both genders, diagnosed with diabetes mellitus type 2 who were treated at the Osijek Health Center. Materials and methods: When visiting family medical clinics, the following data was collected: demographics (gender, age, weight, height) and data collected from laboratory findings (fasting plasma glucose, HbA1c, AST, ALT, urea, creatinine, LDL cholesterol, HDL cholesterol, triglycerides and total cholesterol). Results: Patients who were treated with oral antidiabetics had the lowest HbA1c and fasting plasma glucose concentrations (6,9 % i 7,9 mmol/L), while those who were treated with oral antidiabetics and insulin (combination) had the highest HbA1c and fasting plasma glucose concentrations (9 % i 9,8 mmol/L). The correlation between glycemic regulation parameters (HbA1c, fasting plasma glucose) and age, gender, body mass index was not confirmed. Conclusion: There was a statistically significant difference in HbA1c value between patients on oral antidiabtics therapy and those on combination therapy. There was no statistically significant difference in fasting blood glucose and HbA1c levels in relation to age, gender and body mass index. |
